Since bone mineral parameters were rarely studied in patients receiving SGLT2 inhibitors, we were only able to compare our results with the results of a few other studies in which different SGLT2 inhibitors were administered, and the subjects differed in renal function and diabetes incidence. Here, SLC5A2 is linked to diabetes mellitus.